Prime Minister Narendra Modi on Monday said the two already approved made-in-India COVID-19 vaccines are more cost-effective than any other in the world and have been developed as per the country's needs.
Interacting with chief ministers of all states to discuss the COVID-19 situation and the vaccination roll-out in the country, Modi also said that apart from the two already approved vaccines, four others are in the pipeline.
"Our experts have taken all precautions to provide the countrymen with effective vaccines," he said.
The two approved COVID-19 vaccines in India more cost-effective than other vaccines in the world and have been developed as per our needs and situation, he said.
India is entering a decisive phase of vaccination in the fight against COVID-19, he asserted, pointing that the world's largest vaccination programme will start from January 16.
Public representatives are not part of the three-crore corona warriors and frontline workers to be vaccinated first, Modi said.
In the first phase, the cost of vaccination for these 3 crore people would be borne by the central government, he added.
India's drugs regulator has approved Oxford vaccine Covishield, being manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country.
On Saturday last week, Modi had reviewed the status of COVID-19 and vaccine preparedness across states and union territories at a high-level meeting where.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)